Stock Financial Ratios

ITCI / Intra-Cellular Therapies Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)685.16
Enterprise Value ($M)652.74
Book Value ($M)375.50
Book Value / Share8.65
Price / Book3.27
NCAV ($M)374.80
NCAV / Share8.75
Price / NCAV3.33
Income Statement (mra) ($M)
Net Income-116.43
Balance Sheet (mrq) ($M)
Cash & Equivalents52.34
Cash / Share1.21
Quick Ratio36.86
Current Ratio36.86
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.31
Return on Assets (ROA)-0.30
Return on Equity (ROE)-0.31
Identifiers and Descriptors
Central Index Key (CIK)1567514
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Common Shares Outstanding43,410,277
Common Stock Shares Outstanding43,292,906
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Retained Earnings Per Share0.00
Cash Per Share1.21
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Liabilities Current Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Cash And Equivalents Per Share1.21
Equity Per Share0.00
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Liabilities Per Share0.34
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Assets Current Per Share7.68
Inventory Per Share0.00

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Biotech Forum Daily Digest For February 9th

2018-02-09 seekingalpha
The market continues to be extremely volatile with the Dow dropping another 1,000 points in trading Thursday. (72-1)

Your Daily Pharma Scoop: AbbVie Highlights Pipeline, Novavax Surges, Lipocine Flops At Ad Com

2018-01-12 seekingalpha
Today we will discuss one of the most promising major biopharma companies, AbbVie (ABBV). At the ongoing JP Morgan Healthcare Conference, ABBV CEO Rick Gonzalez gave an overview of the pipeline and financials. The company’s pipeline is the reason we see ABBV as one of the top picks in the major biopharma space. (251-2)

Biotech Forum Daily Digest: Spotlighting A Potential 'Razor & Razor Blade' Story

2017-12-19 seekingalpha
The biotech sector was a yo-yo last week as tax reform winded its way through Congress and due to lack of milestone events as we head into the holidays. (55-4)

Forensic Analysis Value Stock Selections - December

2017-12-01 seekingalpha
Latest update of Positive Forensic returns for all portfolios YTD.  Best return to date: Pos Portfolio (1) July +15.50% to end of November. (33-2)

Your Daily Pharma Scoop: Synergy In 2018, Repatha Action Date, Alkermes Signs Deal

2017-11-28 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (449-1)

CUSIP: 46116X101